Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

The OncFive: Top Oncology Articles for the Week of 4/13

April 19th 2025

Nogapendekin alfa inbakicept sBLA in NMIBC has been filed to FDA for review, a bexmarilimab combination elicits responses in MDS, and more from OncLive.

An EBMT Machine Learning Model Aids With Transplant Risk Stratification in Myelofibrosis

April 18th 2025

Juan Carlos Hernández-Boluda, MD, PhD, discusses the development of an EBMT machine learning model for predicting allo-HCT risk in myelofibrosis.

Dr McLornan on the Challenges of Identifying Optimal Timing for Transplantation in Myelofibrosis

April 18th 2025

Donal McLornan, MBBCh, MRCP, PhD, FRCPath, explains the challenges of choosing optimal timing for allogeneic hematopoietic cell transplantation in myelofibrosis.

Dr Orgueira on the Use of Machine Learning to Predict Survival Outcomes After Allo-HSCT in Myelofibrosis

April 15th 2025

Adrián Mosquera Orgueira, MD, PhD, discusses whether machine learning could accurately predict OS and NRM outcomes after allo-HSCT in myelofibrosis.

Bexmarilimab Plus Azacitidine Meets ORR End Point in R/R Higher-Risk MDS

April 15th 2025

The addition of bexmarilimab to azacitidine elicited an ORR of 63% among patients with relapsed/refractory higher-risk myelodysplastic syndrome.

Dr Hernández-Boluda on the Rationale for Using Machine Learning to Predict Post-HCT Outcomes in Myelofibrosis

April 14th 2025

Juan Carlos Hernández-Boluda, MD, PhD, discusses the rationale for using machine learning to predict OS outcomes after allo-HCT in myelofibrosis.

Five Under 5: Top Oncology Videos for the Week of 4/6

April 13th 2025

The top 5 OncLive videos of the week cover insights in myelofibrosis, chronic lymphocytic leukemia, colorectal cancer, breast cancer, and ovarian cancer.

Dr Rampal on Personalizing Treatment Strategies for Patients With Myelofibrosis

April 10th 2025

Raajit Rampal, MD, discusses typical clinical applications of the 4 FDA-approved JAK inhibitors for the treatment of patients with myelofibrosis.

Dr Sekeres on the Importance of Counseling Patients With MDS on the Benefits of Smoking Cessation

April 7th 2025

Mikkael A. Sekeres, MD, discusses the implications of a study that found associations between smoking intensity and disease progression in MDS.

Oral Decitabine/Cedazuridine Is an Effective, At-Home Treatment Option for MDS and CMML

April 5th 2025

James K. McCloskey II, MD, discusses the advantages of the oral formulation of decitabine plus cedazuridine for patients with MDS and CMML.

Dr McLornan on the Future of an EBMT Machine Learning Model for Identifying and Stratifying Transplant Risk in Myelofibrosis

April 3rd 2025

Donal McLornan, MBBCh, MRCP, PhD, FRCPath, discusses future research directions for an EBMT machine learning model for identifying and stratifying transplant risk in myelofibrosis.

Dr Hernández-Boluda on an EBMT Machine Learning Model for Identifying and Stratifying Transplant Risk in Myelofibrosis

March 31st 2025

Juan Carlos Hernández-Boluda, MD, PhD, discusses an EBMT machine learning–based model for identifying and stratifying transplant risk in myelofibrosis.

Emerging Therapies in Myelofibrosis Could Extend Beyond JAK Inhibitors

March 24th 2025

Raajit Rampal, MD, PhD, discusses current JAK inhibitor treatment options for myelofibrosis and additional therapies being evaluated in clinical trials.

Five Under 5: Top Oncology Videos for the Week of 3/16

March 23rd 2025

The top 5 OncLive videos of the week cover insights in gynecologic cancer, multiple myeloma, urothelial cancer, MPNs, and prostate cancer.

Dr Bhat on the Influence of MPN Risk Stratification on Treatment Decision-Making

March 20th 2025

Seema A. Bhat, MD, discusses typical treatment decisions for patients with myeloproliferative neoplasms based on risk stratification.

Dr Rampal on Emerging Therapies Under Investigation in Myelofibrosis

March 17th 2025

Raajit Rampal, MD, discusses the variety of agents in phase 3 trials for the treatment of patients with myelofibrosis.

Dr Komrokji on Unanswered Questions in High-Risk MDS Management

March 12th 2025

Rami Komrokji, MD, discusses how consensus guidelines could address unanswered questions regarding the management of high-risk MDS.

Imetelstat Earns EU Approval for Transfusion-Dependent Anemia in Lower-Risk MDS